Massive NIH–industry project opens portals to target validation
Elie Dolgin • February 27, 2019
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
Continue reading at Nature Reviews Drug Discovery.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.
Fresh treatments shift the focus from symptom management to repair.